VBI Vaccines, Inc. – (NASDAQ:VBIV)’s share price was down 2.8% during mid-day trading on Tuesday . The stock traded as low as $3.50 and last traded at $3.50, with a volume of 58,504 shares changing hands. The stock had previously closed at $3.60.

Separately, Ladenburg Thalmann started coverage on VBI Vaccines, Inc. – in a research note on Tuesday. They issued a “buy” rating on the stock.

The stock’s 50-day moving average is $3.93 and its 200 day moving average is $3.96. The firm’s market cap is $114.44 million.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned 6.09% of VBI Vaccines, Inc. – at the end of the most recent quarter.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.